40 results about "Goblet cell" patented technology

The application is a divisional application of 2025116336025, the invention provides an application of 2, 4-dihydroxy-6-methoxyacetophenone in preparation of a medicine for treating lacrimal gland secretion dysfunction related diseases, a lacrimal gland dysfunction dry eye mouse model is constructed in the application, and liposome entrapped 2, 4-dihydroxy-6-methoxyacetophenone is adopted for intervention, so that the medicine for treating lacrimal gland secretion dysfunction related diseases is obtained. Experimental results show that the ocular surface function and structure of a model animal are remarkably improved through treatment of 2, 4-dihydroxy-6-methoxyacetophenone, the cornea sodium fluorescein staining score of a mouse in a 2, 4-dihydroxy-6-methoxyacetophenone treatment group is remarkably reduced, and cornea epithelium injury is effectively repaired; the epithelial structure in the cornea tissue tends to be complete, and inflammatory cell infiltration of a matrix layer is obviously relieved; the density of goblet cells in the conjunctiva is obviously increased, which indicates that the secretion function of the mucous layer on the ocular surface is recovered. The treatment of 2, 4-dihydroxy-6-methoxyacetophenone has an improvement trend on tear film rupture time and tear secretion amount, which indicates that the 2, 4-dihydroxy-6-methoxyacetophenone has a potential effect in the aspects of maintaining tear film stability and promoting basic tear secretion.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The invention belongs to the technical field of medicine preparation, and provides an ophthalmic external preparation and a preparation method thereof. According to the ophthalmic external preparation, curcumin included by hydroxypropyl-beta-cyclodextrin loaded on exosome modified by polylysine is adopted as an effective component. The preparation can improve the drug concentration of cornea tissues and realize accurate delivery of ocular surfaces; meanwhile, the exosome and curcumin form a synergistic effect, so that the release of proinflammatory factors such as IL-1beta and TNF-alpha can be inhibited, the secretion of goblet cell mucoprotein and the proliferation of corneal epithelial cells can be promoted, and the tear film rupture time is prolonged; in addition, the preparation is excellent in biocompatibility, free of ocular surface stimulation reaction and high in safety.

The application belongs to the field of biological medicine, and particularly relates to application of DJ-1 in treatment and diagnosis of bronchial asthma. DJ-1 is used as a target in preparation or screening of drugs for bronchial asthma or allergic inflammation; a drug for treating hyperplasia of goblet cells and mucus metaplasia in bronchial asthma, and an animal model for studying inhibition of differentiation of goblet cells and mucus metaplasia. The application identifies, for the first time, an important role of a signal pathway DJ-1 / Ltc4s, which has not been found in eosinophils and lung epithelial cells before, in differentiation of secretory cells into goblet cells, and finds, for the first time, an inhibitory effect of inhibition of the DJ-1 / Ltc4s signal pathway on differentiation of goblet cells in lung epithelial cells through a large number of studies.

The invention discloses a pig jejunum crypt separation and organoid model construction method, and belongs to the technical field of animal tissue separation and culture. The method specifically comprises the following steps: intestinal tract collection, cleaning solution preparation, intestinal tract treatment, tissue trimming, tissue cleaning, digestive juice preparation, tissue digestion, cell mass separation, crypt separation, crypt counting, crypt collection, crypt inoculation and organoid culture. The porcine jejunum organ obtained by the method has a typical three-dimensional cystic structure, has complete epithelial polar and functional cell types, including microvillus, goblet cells, panning cells and endocrine cells, and shows good barrier function and drug metabolic activity. A reliable in-vitro model platform is provided for pig intestinal development, nutrient absorption, pathogen infection mechanism research and precision medical treatment, meanwhile, a technical foundation is laid for large-scale application of organoids, and the method has important scientific significance and clinical value.

This invention discloses an oral frameshift peptide neoantigen vaccine, its preparation method, and its application, relating to the field of biomedical technology. The preparation method includes: 1) synthesizing a sea urchin-like metal-organic framework (MOF) via a hydrothermal method using zinc ions and 3,3''-dihydroxy-2',5'-dimethyl-[1,1':4',1''-terphenyl]-4,4''-dicarboxylic acid; 2) loading the sea urchin-like MOF with a frameshift peptide and a Toll-like receptor 9 agonist via electrostatic interactions and / or van der Waals forces to prepare the oral frameshift peptide neoantigen vaccine. This vaccine not only promotes antigen endocytosis and transcytosis via intestinal microfold cells by activating cyclin 42, but also alleviates immune tolerance mediated by the goblet cell-regulatory T cell immunosuppressive axis and activates specific CD8+. + T cells help prevent the development of Lynch syndrome-related colorectal cancer.

The application discloses a lactobacillus taiwanensis with enhanced intestinal barrier function and application thereof, and belongs to the technical field of microorganisms and medicine. The lactobacillus taiwanensis is preserved in the Guangdong Microbial Culture Collection Center, and the preservation number is GDMCC No.63714. The intestinal barrier enhancement and protection of the lactobacillus taiwanensis CCFM1318 are embodied in the following aspects: (1) the lactobacillus taiwanensis CCFM1318 has good in-vitro gastrointestinal tolerance, strong adhesion to intestinal epithelial cells and strong colonization in the gastrointestinal tract; (2) the lactobacillus taiwanensis CCFM1318 significantly up-regulates the expression level of tight junction protein related genes in Caco-2 cells after DSS stimulation; (3) the bacterial-free culture medium supernatant of the lactobacillus taiwanensis CCFM1318 can promote the expression and secretion of MUC2 of the LS 174T goblet cell line, and can improve the expression of MUC2 after endoplasmic reticulum stress, thereby enhancing and protecting the intestinal barrier. The lactobacillus taiwanensis CCFM1318 has great application prospect in products (such as food or medicine) for enhancing and protecting the intestinal barrier.

The invention provides a donkey milk exosome preparation, a preparation method and application, and belongs to the technical field of life sciences, the donkey milk exosome preparation comprises a donkey milk exosome and a complex microbial inoculant; wherein the complex microbial inoculant is prepared from clostridium butyricum, bacillus subtilis and enterococcus faecium. The scheme that the donkey milk exosome and the complex microbial inoculant are compounded for use is created for the first time, and the donkey milk exosome and the complex microbial inoculant can achieve synergistic interaction, so that inflammatory factors can be effectively reduced, the number of goblet cells is increased, and the intestinal mucosa is repaired; meanwhile, by utilizing the natural anti-inflammatory property of the donkey milk exosome and the micro-ecological regulation of the complex microbial inoculant, the side effects of chemical drugs are avoided, and an integrated scheme of'intestinal barrier repair-immune regulation 'is provided.

The invention discloses bifidobacterium breve for regulating metabolism of vitamin A in intestinal flora and application of the bifidobacterium breve, and belongs to the field of microorganisms. According to the bifidobacterium breve CCFM1489 disclosed by the invention, vitamin A can be subjected to external metabolism to generate retinoic acid; corneal injury and conjunctival goblet cell injury of mice with xerophthalmia are relieved; the RA level in serum of the dry-eye mouse is improved; the levels of IL-6, IL-17 and TNF-alpha in serum of the mouse with the dry eye syndrome are reduced, the intestinal flora of the mouse with the dry eye syndrome is regulated, and the abundance of beneficial bacteria is increased. Therefore, the bifidobacterium breve CCFM1489 has a huge application prospect in preparation of products for preventing and / or relieving xerophthalmia.

The application discloses a prillium fimicola for relieving ulcerative colitis and application thereof, and belongs to the technical field of microorganisms. The prillium fimicola N03 can improve body weight loss and disease activity index increase caused by ulcerative colitis, inhibit colon atrophy, protect the integrity of colon tissue structure, increase the number of goblet cells, reduce the inflammation level in the intestinal tract, can significantly up-regulate the expression of Nrf2 , Gpx2 and Nqo1 in the body of a mouse with colitis, effectively improve the impaired activation of Nrf2 signal pathway in the body of the mouse, and has a good relieving effect on colitis. The prillium fimicola N03 has a very wide application prospect when used for preparing a medicine composition for relieving ulcerative colitis and a fermented food.​​​​​​​​

This invention relates to the fields of biomedicine and food nutrition, specifically to the application of purple sweet potato anthocyanins in the preparation of products for preventing or improving intestinal aging. This invention demonstrates that purple sweet potato anthocyanins can significantly improve the degenerative changes and barrier fragility of the colon caused by natural aging, restore colonic crypt morphology and epithelial ultrastructure, and upregulate the expression of tight junction proteins and mucus barrier-related indicators. Furthermore, purple sweet potato anthocyanins can effectively enhance crypt proliferation activity and promote the differentiation of intestinal stem cells into secretory lineages (such as goblet cells and enteroendocrine cells). Its mechanism of action does not rely on direct anti-inflammatory pathways, but rather on remodeling intestinal flora metabolism (such as increasing short-chain fatty acids) and activating intestinal cell autophagy via the PI3K-Akt signaling pathway, thereby supporting the continuous renewal and maintenance of the intestinal barrier. This invention provides a new approach for the development and application of food-derived polyphenols targeting the gut to promote healthy aging.

The invention provides application of barley pest larva defatted protein powder in preparation of drugs for treating inflammatory bowel diseases. The invention belongs to the technical field of medicine, and by establishing a dextran sodium sulfate induced mouse IBD model and lavaging barley pest larva defatted protein powder, it is found that the traditional Chinese medicine composition can relieve IBD mouse colitis symptoms, restore colon length, relieve mucosal lesion, retain goblet cell and crypt structures, reduce inflammatory cell infiltration and down-regulate inflammatory cytokine expression; the compound is expected to play an important role in preparing medicines for treating inflammatory enteritis.

The application relates to application of spondias mombin extract in preparation of medicines for preventing and / or treating chronic colitis, and belongs to the technical field of biological medicines. The spondias mombin extract with a polysaccharide content of more than 60% can relieve the shortening of the colon, reduce intestinal inflammatory cell infiltration, surface epithelial damage and loss of goblet cells, and reduce the DAI score and the histological double-blind score of an animal model, so that the spondias mombin extract can play a role in treating chronic colitis.

The application discloses an active peptide for regulating intestinal epithelial mucus barrier function and a preparation method and application thereof, and belongs to the technical field of bioengineering, wherein the amino acid sequence of the active peptide is shown as SEQ ID NO: 1, 2, 3, 4, 5 or 6. The application takes duck skin as raw material, extracts a protein extract, carries out enzymolysis, collects low-molecular-weight peptide components through ultrafiltration grading, carries out freeze-drying to obtain active peptide crude powder, and then carries out screening and separation and purification on the active peptide crude powder through an intestinal epithelial mucus barrier damage model to obtain a target active peptide. The active peptide can significantly improve the secretion level of mucin, promote the expression of a MUC2 gene, maintain the secretion function of goblet cells, restore the integrity of a mucus layer, effectively improve the damaged intestinal epithelial mucus barrier function under the stimulation of inflammation and oxidation stress, and block the contact between pathogenic microorganisms and toxins and epithelial cells. The active peptide obtained by the application has clear structure and definite function, and provides a new way for high-value utilization of livestock and poultry by-products and development of intestinal health products.

The invention provides an M2 macrophage exosome loaded canagliflozin nano-drug and application thereof, an M2 macrophage exosome is used as a carrier, and canagliflozin is loaded on the M2 macrophage exosome. The Exo-CANA delivery system is constructed for the first time, the exosomes are small in size, the phagocytosis of mononuclear macrophages can be effectively avoided, the exosomes can freely penetrate through vascular walls and extracellular matrixes, Th2 type airway inflammation, goblet cell metaplasia and pulmonary interstitial collagen deposition can be remarkably improved, and the treatment effect is remarkably superior to that of a CANA single-drug treatment group and an M2-Exos single-drug treatment group.

The invention provides a plant lactobacillus MLPCO23 resistant to PEDV (porcine epidemic diarrhea virus) infection and application of the plant lactobacillus MLPCO23, and belongs to the technical field of microorganisms. The preservation number of the plant lactobacillus MLPCO23 is CCTCC (China Center for Type Culture Collection) NO: M 20252370. The plant lactobacillus MLPCO23 can be colonized in intestinal tracts, has a remarkable PEDV (porcine epidemic diarrhea virus) resisting effect, and can be used for improving the PEDV infection resisting capability of piglets and relieving clinical symptoms caused by PEDV infection. The plant lactobacillus MLPCO23 can repair intestinal villi and close connection structures, increase the number of goblet cells and maintain the steady state of intestinal barriers. The plant lactobacillus MLPCO23 serving as intestinal probiotics provides a new intervention target and a prevention and control strategy for PEDV infection, and also provides a new thought and a new clue for clarification of the effect and mechanism of Min pig flora for regulating intestinal mucosa microecology and resisting PEDV infection.

This invention belongs to the technical field of biomedicine and discloses the application of a composition comprising neo-agar oligosaccharides and astaxanthin in the preparation of formulations for the treatment of dry eye syndrome, as well as the formulation of in-situ gel eye drops and its preparation method. The composition provided by this invention specifically comprises neo-agar oligosaccharides and astaxanthin, which together constitute an organic whole, synergistically contributing to excellent ocular surface retention time and penetration efficiency. It can effectively inhibit the activation of core inflammatory pathways at low doses, reduce inflammatory cell infiltration in ocular surface tissues, promote goblet cell proliferation and epithelial repair, increase tear secretion, and improve corneal epithelial integrity. This achieves multiple effects, including anti-inflammatory properties, increased tear secretion, reduced corneal damage, promotion of ocular surface tissue repair, and improvement of corneal epithelial integrity. Furthermore, the composition exhibits excellent ocular surface biocompatibility and has very promising application prospects in the preparation of formulations for the treatment of dry eye syndrome.

The invention provides bifidobacterium breve NKU BB 1-13 and application thereof, and belongs to the technical field of microorganisms. The invention provides a bifidobacterium breve NKU BB 1-13, and the preservation number of the bifidobacterium breve NKU BB 1-13 is GDMCC No: 65957. In the invention, the bifidobacterium breve NKU BB 1-13 cannot generate nitrate reductase, shows negative ornithine and lysine decarboxylase, has no hemolytic activity, and is a safe strain. The bifidobacterium breve NKU BB 1-13 has the characteristics of acid resistance and cholate resistance, and can tolerate the digestion environment of gastrointestinal tracts. The bifidobacterium breve NKU BB 1-13 can relieve oxidative stress and inflammation of intestinal tracts in the aging process, meanwhile, can promote goblet cells to secrete intestinal barrier protein and improve the intestinal barrier function, and then can improve intestinal health in the aging process.

The invention is a divisional application of which the application number is 2025116336025. The invention provides an application of arnica diol in preparation of a medicine for treating lacrimal gland secretion dysfunction related diseases, and relates to the technical field of biomedicine.A lacrimal gland dysfunction dry-eye mouse model is constructed, and liposome entrapped arnica diol is adopted for intervention, so that the medicine for treating lacrimal gland secretion dysfunction related diseases is obtained. Experimental results show that the ocular surface function and structure of model animals are remarkably improved through arnica glycol treatment, the sodium corneal fluorescein staining score of mice in an arnica glycol treatment group is remarkably reduced, and corneal epithelium injuries are effectively repaired; the epithelial structure in the cornea tissue tends to be complete, and inflammatory cell infiltration of a matrix layer is obviously relieved; the density of goblet cells in the conjunctiva is obviously increased, which indicates that the secretion function of the mucous layer on the ocular surface is recovered. And the arnica glycol treatment has an improvement trend on tear film rupture time and tear secretion volume, which indicates that the arnica glycol has a potential effect in the aspects of maintaining tear film stability and promoting basic tear secretion.

The application provides application of Elaeagnus conferta polysaccharide in preparation of a medicine for treating intestinal barrier related diseases, and relates to the technical field of natural medicine chemistry. The intestinal protection effect of the Elaeagnus conferta polysaccharide on a dextran sodium sulfate induced intestinal injury model of mice is investigated, and the research result shows that the Elaeagnus conferta polysaccharide can treat clinical symptoms such as diarrhea, enteritis and weight loss caused by intestinal barrier injury, significantly reduces disease scores, inhibits colonic tissue goblet cell necrosis, promotes secretion of mucin, increases expression of tight junction proteins, and enhances intestinal mucosal barrier function. As a widely planted fruit and a fruit loved by the public, the Elaeagnus conferta has the advantages of high safety and easy acquisition. It is expected to become an effective active ingredient source for resisting intestinal injury diseases, and has a broad market development prospect.

This invention provides the application of *Pleurotus oosporum* polysaccharide in the preparation of drugs and health foods that regulate intestinal barrier function or protect against intestinal damage-related diseases. Its protective effect against a mouse model of intestinal damage induced by sodium dextran sulfate was investigated. Results showed that *Pleurotus oosporum* polysaccharide significantly improved symptoms such as weight loss, loose stools, and colonic atrophy caused by intestinal damage in mice, reduced the disease activity index, inhibited colonic epithelial destruction, inflammatory cell infiltration, and goblet cell necrosis, and enhanced intestinal mucosal barrier function. As a fungus, *Pleurotus oosporum* has high safety and is a potential source of active ingredients against intestinal damage, showing promising development prospects in intestinal barrier protection.

The invention discloses a method for evaluating potential airway epithelial toxicity of inhalable particles based on organoids, and relates to the technical field of toxicity detection. According to the method for evaluating the potential airway epithelium toxicity of the inhalable particles based on the human ciliary eversion airway organ, objective quantitative analysis on the epithelium structure (epithelium thickness) and the cell function (ciliary movement and goblet cell secretion) of the human airway is realized; a rapid and accurate evaluation method is provided for inhalation toxicity research of various types of inhalable particles.

Systems and methods involve abrading a patient lung airway wall to reduce mucus production therein. Exemplary techniques include rotationally and / or linearly oscillating an abrasive material against the airway wall so as to damage mucus producing tissues, for example by removing goblet cells, while destroying less than the entire airway wall. The abrasive material may be present on the surface of an expandable balloon body or another expandable device, which can be delivered to the patient treatment site via a bronchoscope. In some cases, the abrasion techniques can cause cell damage or death at a controlled or predetermined tissue depth.

The application is a divisional application of 2025116336025, the invention provides an application of diserpine in preparation of drugs for treating lacrimal gland secretion dysfunction related diseases, and the technical key points are as follows: in the application, a lacrimal gland dysfunction dry eye mouse model is constructed, and lipidosome entrapped diserpine is adopted for intervention. Through comprehensive analysis of multiple physiological and histological indexes, the ocular surface function and structure of the model animal are remarkably improved through diserine treatment. Specifically, compared with a model control group, the corneal fluorescein sodium staining score of mice in a diserine treatment group is remarkably reduced, which indicates that the corneal epithelium injury is effectively repaired; meanwhile, the epithelium structure in the cornea tissue tends to be complete, and inflammatory cell infiltration of a matrix layer is obviously relieved; the density of goblet cells in the conjunctiva is also remarkably increased, which indicates that the secretion function of the mucous layer on the ocular surface is recovered. And the diserpine treatment has an improvement trend on tear film rupture time and tear secretion volume, which indicates that the diserpine has a potential effect in the aspects of maintaining tear film stability and promoting basic tear secretion.

The invention discloses application of bifidobacterium longum subsp.infantis capable of improving physiological activity of vitamin A in xerophthalmia, and belongs to the field of microorganisms. According to the bifidobacterium longum subsp. Infantis CCFM1426 disclosed by the invention, vitamin A can be subjected to external metabolism to generate retinoic acid; the infiltration of ulcerative colitis in mice is relieved; the RA level of the mouse colon with ulcerative colitis is improved; the levels of IFABP and DAO in serum of mice with ulcerative colitis are reduced; corneal injury and conjunctival goblet cell injury of mice with xerophthalmia are relieved; the RA level in serum of the dry-eye mouse is improved; the levels of IL-6 and IL-17 in serum of mice with xerophthalmia are reduced. Therefore, the bifidobacterium longum subsp. Infantis CCFM1426 has a huge application prospect in preparation of products for preventing and / or relieving xerophthalmia.

The application provides a polypeptide type PROTAC molecule targeting degradation of a STING protein and application thereof in treatment of dry eye, and belongs to the technical field of biotechnology.The polypeptide type PROTAC molecule provided by the application comprises a STING targeting unit capable of specific binding with the STING protein, a connecting arm and an E3 ubiquitin ligase ligand, and can specifically degrade the STING protein.The application further provides application of the polypeptide type PROTAC molecule in preparation of a medicine for treating and / or preventing dry eye and a medicine for preventing and / or treating dry eye, has significant anti-inflammatory and tissue protection effects, can improve corneal epithelial damage, inflammatory reaction and goblet cell loss, and has excellent biocompatibility and safety, and is suitable for long-term or repeated administration on an ocular surface.

The invention relates to the technical field of functional food processing, in particular to a method for enhancing intestinal barrier function regulating activity of galactooligosaccharide based on collagen peptide Maillard coupling and application of the method. According to the method for enhancing the intestinal barrier regulating activity of the galactooligosaccharide based on Maillard coupling of the collagen peptide, provided by the invention, the biological effect of the galactooligosaccharide in the aspect of regulating the intestinal barrier function can be remarkably improved; meanwhile, the obtained Maillard conjugate has remarkable advantages in the aspects of promoting mucous secretion of goblet cells, up-regulating expression of tight junction proteins ZO-1 and Occludin and reducing intestinal permeability. The method provided by the invention is simple and convenient to operate, industrialization is easy to realize, the obtained product can be used as a functional component related to intestinal health to be applied to the fields of food, functional food and the like, and the application value of galactooligosaccharide can be effectively improved.

The application relates to the field of intelligent medical treatment, in particular to a method, equipment and program product for identifying rare intestinal diseases. The method comprises the following steps: acquiring pathological data of a to-be-detected person; the pathological data comprises goblet cells, Paneth cells, neutrophilic granulocytes and plasma cells; the type of the rare intestinal disease of the to-be-detected person is determined based on the pathological data, the type of the rare intestinal disease comprises autoimmune enteropathy and common variant immunodeficiency; when any two or more of the following conditions are met, namely, the number of goblet cells is less than a preset threshold, the number of Paneth cells is less than a preset threshold, neutrophilic granulocyte infiltration occurs, and the number of plasma cells remains unchanged, the to-be-detected person is determined to have autoimmune enteropathy; and when the number of plasma cells is less than a preset threshold, the to-be-detected person is determined to have common variant immunodeficiency. The application can effectively distinguish the types of rare intestinal diseases and has good clinical value.

The invention discloses a method, a system, equipment, a medium and a program product for evaluating an intestinal hypoxia state. Two specific goblet cell subgroups capable of representing the intestinal hypoxia state are found for the first time through single cell transcriptome sequencing, and the two specific goblet cell subgroups comprise a first goblet cell subgroup jointly marked by a Sytl2 gene, a Sytl3 gene, a Sytl5 gene, a Rab27a gene, a Rab27b gene and an Mlph gene and a second goblet cell subgroup jointly marked by an Fcgbp gene, a Tff3 gene, an Agr2 gene, a Ptprn2 gene, an Fer1l6 gene, a Muc2 gene and an Mlph gene. On the basis, the invention provides a method, a system, equipment, a medium or a program product for evaluating the intestinal hypoxia state for the field so as to assist a doctor in evaluating the intestinal hypoxia state of a patient and guide a clinician to formulate a personalized treatment scheme for the patient.

The application provides a new use of NU6300 and belongs to the technical field of medicine.The application provides a new use of NU6300 in inhibiting pyroptosis.Furthermore, the application verifies that NU6300 has a therapeutic effect on colitis by inhibiting pyroptosis, significantly reducing DSS-induced epithelial and mucosal damage, crypt expansion and goblet cell depletion, and verifies that NU6300 has a protective effect on LPS-induced sepsis by inhibiting pyroptosis, and the protective effect of NU6300 on LPS-induced sepsis is superior to that of NSA.It is proved that NU6300 can play an important role in the treatment of diseases mediated by pyroptosis and has good clinical application value.